{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:56:47Z","timestamp":1789016207128,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jtct.2024.03.004","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T21:58:51Z","timestamp":1709935131000},"page":"520.e1-520.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"30","author":[{"given":"Ayman","family":"Sayyed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Gerbitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Dong Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9251-3609","authenticated-orcid":false,"given":"Arjun Datt","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios V.","family":"Michelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-3117","authenticated-orcid":false,"given":"Igor","family":"Novitzky-Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auro","family":"Viswabandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-0113","authenticated-orcid":false,"given":"Ivan","family":"Pasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jtct.2024.03.004_bib0001","first-page":"2144","article-title":"Recognition of common childhood malignancies","volume":"61","author":"Young","year":"2000","journal-title":"Am Fam Physician"},{"issue":"10230","key":"10.1016\/j.jtct.2024.03.004_bib0002","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jtct.2024.03.004_bib0003","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2024.03.004_bib0004","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.03.004_bib0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/asheducation-2018.1.137","article-title":"Genetics and prognosis of ALL in children vs adults","volume":"2018","author":"Roberts","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"10.1016\/j.jtct.2024.03.004_bib0006","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","article-title":"Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands","volume":"18","author":"de Bont","year":"2004","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jtct.2024.03.004_bib0007","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jtct.2024.03.004_bib0008","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1080\/10428194.2021.1910688","article-title":"Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data","volume":"62","author":"Pasic","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2024.03.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/OP.21.00843","article-title":"Updates in the management of relapsed and refractory acute lymphoblastic leukemia: an urgent plea for new treatments is being answered!","volume":"18","author":"DuVall","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"10.1016\/j.jtct.2024.03.004_bib0010","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2024.03.004_bib0011","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2024.03.004_bib0012","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"issue":"suppl 2","key":"10.1016\/j.jtct.2024.03.004_bib0013","first-page":"LBA","volume":"140","author":"Litzow","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.03.004_bib0014","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.HS9.0000843352.55138.40","article-title":"S114: ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results from a phase II study","volume":"6","author":"Short","year":"2022","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.jtct.2024.03.004_bib0015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jtct.2024.03.004_bib0016","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/bloodadvances.2021005579","article-title":"Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis","volume":"6","author":"Locatelli","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2024.03.004_bib0017","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"Gokbuget","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jtct.2024.03.004_bib0018","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/s41409-021-01279-w","article-title":"Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data","volume":"56","author":"Badar","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jtct.2024.03.004_bib0019","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","article-title":"How I assess comorbidities before hematopoietic cell transplantation","volume":"121","author":"Sorror","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2024.03.004_bib0020","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2024.03.004_bib0021","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"446","key":"10.1016\/j.jtct.2024.03.004_bib0022","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"10.1016\/j.jtct.2024.03.004_bib0023","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"10.1016\/j.jtct.2024.03.004_bib0024","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1089\/scd.2014.0123","article-title":"Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis","volume":"23","author":"Abdul Wahid","year":"2014","journal-title":"Stem Cells Dev"},{"issue":"3","key":"10.1016\/j.jtct.2024.03.004_bib0025","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2013.253","article-title":"Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease","volume":"28","author":"Bachanova","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jtct.2024.03.004_bib0026","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/ajh.23465","article-title":"Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission","volume":"88","author":"Eom","year":"2013","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2024.03.004_bib0027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1179\/1607845414Y.0000000175","article-title":"Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond","volume":"20","author":"Hwang","year":"2015","journal-title":"Hematology"},{"issue":"11","key":"10.1016\/j.jtct.2024.03.004_bib0028","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/bmt.2013.68","article-title":"Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)","volume":"48","author":"Tanaka","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.03.004_bib0029","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jtct.2023.01.017","article-title":"Post-transplantation sinusoidal obstruction syndrome in adult patients with B cell acute lymphoblastic leukemia treated with pretransplantation inotuzumab","volume":"29","author":"Agrawal","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2024.03.004_bib0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10428194.2020.1827247","article-title":"Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin","volume":"62","author":"Ladha","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jtct.2024.03.004_bib0031","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2024.03.004_bib0032","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ccr3.604","article-title":"Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell transplant","volume":"4","author":"Khan","year":"2016","journal-title":"Clin Case Rep"},{"issue":"23","key":"10.1016\/j.jtct.2024.03.004_bib0034","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1002\/cncr.32335","article-title":"Transplantation in adults with relapsed\/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2024.03.004_bib0035","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bbmt.2020.01.029","article-title":"Outcomes of allogeneic hematopoietic cell transplantation after salvage therapy with blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"26","author":"Salhotra","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.03.004_bib0036","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11899-020-00579-0","article-title":"Hematopoietic cell transplantation for Philadelphia chromosome negative adult acute lymphoblastic leukemia in the modern era of immune therapy","volume":"15","author":"Yurkiewicz","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"10.1016\/j.jtct.2024.03.004_bib0037","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.bbmt.2018.07.008","article-title":"Reduced-intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies","volume":"24","author":"Law","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2024.03.004_bib0038","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/j.bbmt.2019.07.005","volume":"25","author":"Salas","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.03.004_bib0039","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/ejh.13321","article-title":"Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia","volume":"103","author":"Salas","year":"2019","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2024.03.004_bib0040","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/ejh.13327","article-title":"Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis","volume":"103","author":"Salas","year":"2019","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2024.03.004_bib0041","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41409-020-0813-9","article-title":"Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD","volume":"55","author":"Salas","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.03.004_bib0042","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000507536","article-title":"Post-transplant cyclophosphamide combined with anti-thymocyte globulin as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplantation in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"144","author":"Alanazi","year":"2021","journal-title":"Acta Haematol"},{"issue":"5","key":"10.1016\/j.jtct.2024.03.004_bib0043","doi-asserted-by":"crossref","first-page":"265.e1","DOI":"10.1016\/j.jtct.2022.02.001","article-title":"Improving safety and outcomes after allogeneic hematopoietic cell transplantation: a single-center experience","volume":"28","author":"Salas","year":"2022","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724002550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724002550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T19:39:46Z","timestamp":1746128386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724002550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2666636724002550"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.03.004","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}